Physiologic effects of doxapram in idiopathic apnea of prematurity.
Twelve premature infants with significant apnea of prematurity while receiving therapeutic doses of aminophylline were given an intravenous infusion of doxapram, 2 or 2.5 mg/kg/hr. The ventilatory effects of the medication were monitored by means of face mask spirometry and airway occlusion studies. Doxapram therapy was associated with significant increases in minute ventilation, tidal volume, mean inspiratory flow, and airway pressure 100 msec after occlusion. Respiratory frequency and the relative duration of inspiration and expiration were unchanged. Paco2 decreased significantly during the infusion. The apnea attack rate, monitored by continuous recording, was significantly reduced after the first 6 hours of therapy. Six hours after starting doxapram, mean arterial blood pressure was significantly elevated, and continued to increase during the 24 hours of therapy. Doxapram is effective in treatment of apnea of prematurity refractory to aminophylline, and appears to act by increasing respiratory center output.
Barrington
K J
KJ
Finer
N N
NN
Peters
K L
KL
Barton
J
J
D000628:Aminophylline / Q000627:therapeutic use; D001049:Apnea / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D001724:Birth Weight; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D004315:Doxapram / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D007263:Infusions, Parenteral; D008991:Monitoring, Physiologic; D012121:Respiration, Artificial; D012125:Respiratory Center / Q000187:drug effects; D012129:Respiratory Function Tests; D013997:Time Factors
D002245:Carbon Dioxide; D000628:Aminophylline; D004315:Doxapram